Despite COVID-19 crisis Securities & Exchange Commission whistleblower actions and awards mount

Despite the COVID-19 crisis, the Securities & Exchange Commission has continued to increase multi-million dollar awards awards under its Dodd-Frank whistleblower program. Since January 21, 2020, when the CDC confirmed the first case of COVID-19 in the United States, the SEC has issued 12 whistleblower awards totaling approximately $64 million. Some of the highlights of these...
Continue reading…

Newman Law Offices announces settlement Encore Rehabilitation to pay $4.033 Million to settle whistleblower case

  Skilled Nursing Rehabilitation and Therapy company, Encore Rehabilitation Services, LLC (Encore) which services hundreds of skilled nursing facilities in 25 states will pay $4,033,346 with interest settling a False Claims Act lawsuit alleging healthcare fraud. The case, captioned UNITED STATES EX REL REZA SAFFARIAN AND AUDREY THEILE V. ENCORE REHABILITATION SERVICES, LLC ET AL...
Continue reading…

Newman Law Offices False Claims Act whistleblower case against nursing home chain Saber Healthcare settles for $10 Million

The nursing home chain, Saber Healthcare Group LLC, and related entities, (Saber) have agreed to pay $10 million to settle a whistleblower case alleging that Saber violated the False Claims Act by knowingly causing certain of its skilled nursing facilities (SNFs) to submit false claims to Medicare for rehabilitation therapy services that were not...
Continue reading…

Cryptocurrency company owner targeting docs with proprietary alogorithm said to get extraordinary profits charged by SEC with fraud

The Securities and Exchange Commission  filed charges against an Ohio-based businessman who allegedly orchestrated a digital asset scheme that defrauded approximately 150 investors, including many physicians. The SEC alleges that Michael W. Ackerman, along with two business partners, raised at least $33 million by claiming to investors that...
Continue reading…

Sanofi charged in Depakine epilepsy drug that causes birth defects and impedes neurological development in pregnant patients.

The Global pharma company Sanofi has been formally charged over Depakine, a  therapy for epilepsy that causes birth defects and impedes neurological development when taken during pregnancy. The compound sodium valproate was deemed to cause neurodevelopmental risks emerged. In 2015, authorities recommended that practitioners should no longer prescribe the treatment for women of childbearing...
Continue reading…